Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LPMix vaccine
- Development stage
- Preclinical
- Lead developer
- University of Alberta
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Administration
- Intranasal
01
Overview
**LPMix vaccine** is an experimental intranasal lipopeptide-based mucosal vaccine candidate developed at the University of Alberta for prevention of coronavirus disease 2019. It comprises seven palmitoylated SARS-CoV-2 epitope lipopeptides, LP1 through LP7, derived from conserved functional regions of the viral spike, nucleocapsid, and membrane proteins. The self-assembling lipopeptides are intended to generate antigen-specific mucosal IgA, systemic IgM and IgG, and memory CD4-positive and CD8-positive T-cell responses. In mouse and hamster studies, LPMix induced cross-variant immune responses against Alpha, Beta, Delta, and Omicron SARS-CoV-2 variants; addition of heat-killed Caulobacter crescentus enhanced mucosal and durable immune responses. ([frontiersin.org](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1619882/pdf))
- Other names
- LP MixLPMix
02
Targets
SARS-CoV-2 spike protein conserved peptide epitopes
Beyond the preview
Go deeper on LPMix vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LPMix vaccine.